Related Experiment Video
Updated: Jun 28, 2025
A Mice Model of Chlorhexidine Gluconate-Induced Peritoneal Damage
Published on: April 28, 2022
SGLT-2 inhibitors as novel treatments of multiple organ fibrosis
Junpei Hu1, Jianhui Teng2, Shan Hui1
1Department of Geriatrics, Hunan Provincial People's Hospital, The First Affiliated Hospital of Hunan Normal University, China.
Abstract:
Fibrosis, a significant health issue linked to chronic inflammatory diseases, affects various organs and can lead to serious damage and loss of function. Despite the availability of some treatments, their limitations necessitate the development of new therapeutic options. Sodium-glucose cotransporter 2 inhibitors (SGLT2i), known for their glucose-lowering ability, have shown promise in offering protective effects against fibrosis in multiple organs through glucose-independent mechanisms. This review explores the anti-fibrotic potential of SGLT2i across different tissues, providing insights into their underlying mechanisms and highlighting recent research advancements. The evidence positions SGLT2i as a potential future treatments for fibrotic diseases.
Insights
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) show promise in treating organ fibrosis. These drugs offer protective effects against fibrosis through glucose-independent mechanisms, suggesting potential new therapeutic options.
Area of Science:
- Cardiovascular Research
- Nephrology
- Endocrinology
Background:
- Fibrosis is a major complication of chronic inflammatory diseases, causing organ damage and dysfunction.
- Current treatments for fibrosis are limited, driving the need for novel therapeutic strategies.
- Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are primarily known for glucose lowering in diabetes.
Purpose of the Study:
- To review the anti-fibrotic potential of SGLT2i across various organs.
- To elucidate the glucose-independent mechanisms underlying SGLT2i's anti-fibrotic effects.
- To highlight recent advancements in SGLT2i research for fibrotic diseases.
Main Methods:
- Literature review of preclinical and clinical studies.
- Analysis of studies investigating SGLT2i in different fibrotic models.
- Synthesis of evidence on SGLT2i's impact on fibrotic pathways.
Main Results:
- SGLT2i demonstrate protective effects against fibrosis in multiple organs, including the heart, kidneys, and liver.
- Evidence suggests these benefits are mediated by mechanisms independent of glucose lowering.
- Key mechanisms include reduction of inflammation, oxidative stress, and TGF-β signaling.
Conclusions:
- SGLT2i exhibit significant anti-fibrotic properties across diverse tissues.
- Their glucose-independent actions present a promising therapeutic avenue for fibrotic conditions.
- Further research supports SGLT2i as potential future treatments for fibrotic diseases.
